Zevra Therapeutics, Inc. (1GDA.F)

4,3200 -0,0600 (-1,37%) Börsenschluss: 08:01AM CEST

Zevra Therapeutics, Inc.

1180 Celebration Boulevard
Suite 103
Celebration, FL 34747
United States
321 939 3416
https://zevra.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 65

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Neil F. McFarlane	President, CEO & Director	462,64k	N/A	1973
Ms. Christal M. M. Mickle M.A.	Co-Founder & Chief Development Officer	571,54k	N/A	1979
Mr. R. LaDuane Clifton CPA	CFO, Secretary & Treasurer	604,67k	N/A	1972
Mr. Joshua M. Schafer M.B.A.	Chief Commercial Officer & Executive VP of Business Development	703,52k	N/A	1972
Dr. Sven Guenther Ph.D.	Chief Scientific Officer	456,66k	N/A	1972
Ms. Nichol L. Ochsner	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Christopher M. Lauderback Ph.D.	Senior Vice President of Manufacturing	N/A	N/A	1975
Dr. Rene A. Braeckman Ph.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Daniel Gallo Ph.D.	Senior Vice President of Medical Affairs & Advocacy	N/A	N/A	N/A
Dr. Adrian Quartel FFPM, M.D.	Chief Medical Officer	N/A	N/A	1961

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Corporate Governance

Zevra Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 4, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.